Lovable raises $400m backed by EU’s Scaleup Fund
THE SO WHAT
A €400M raise backed by the EU’s Scaleup Fund shows Europe is willing to write late-stage checks to keep its growth companies local. If you’re a European founder, the calculus between flipping to US capital and staying in-region is shifting — expect more conditional but sizable domestic support.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VenturePartnering with Preview: Lights, Inference, Action
Sequoia backing Preview is another data point that inference-time orchestration — not just bigger base models — is where venture dollars see defensible value. If you’re building in applied AI, expect investor diligence to center on how you manage context, tools, and latency at inference, not just your fine-tune story.
Startups & VentureMegadeals took 87.5% of US venture dollars, and the rest of the market is priced by vintage
When 87.5% of US venture dollars go into $100M+ rounds, capital for sub-megadeal companies stops being about sector and starts being about when you last raised. If you’re not in the AI megadeal club, plan for a vintage discount on your next round and manage burn like external up-rounds are rare, not assumed.
Startups & VentureMark Bezos’ Fund Faces Fight to Recoup Losses From Fence Startup
A $11.7M "Uber for fences" implosion ending in fraud claims is a reminder that marketplace gloss doesn’t fix low-frequency, operationally gnarly services. For early-stage investors and operators, the bar on unit economics and governance in "X for Y" plays is going up, even when the cap table has marquee names.
Startups & VentureSeattle longevity startups unite: Viome acquires plasma exchange pioneer Circulate Health
Viome buying Circulate Health for an estimated $15M–$50M is a small-dollar but clear signal that longevity startups are consolidating diagnostics and intervention under one roof. If you’re in the space, expect more vertical integration plays that bundle testing, protocols, and subscription care into a single consumer relationship.